CDT
NASDAQConduit Pharmaceuticals
$4.08
-1.81 (-30.73%)
2026-04-10 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$19.9M
P/E Ratio
N/A
52W Low
52W High
$0.37
$11.00
Volume
142K
About Conduit Pharmaceuticals
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has stra...
Employees
6
Website
conduitpharma.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $2.72B | 11.6% | $237.5M | $491.0M |
| 2024 | $922.2M | -1.7% | -$17.8M | -$9.6M |
| 2023 | N/A | N/A% | -$535K | -$7.7M |
| 2022 | N/A | N/A% | -$4.9M | -$2.3M |
| 2021 | N/A | N/A% | -$3.7M | -$2.2M |
| 2025 Q4 | $720.1M | 46.0% | $255.4M | $309.3M |
| 2025 Q3 | $698.2M | -1.0% | -$7.1M | $144.7M |
| 2025 Q2 | $672.0M | -0.7% | -$6.0M | -$2.6M |
| 2025 Q1 | $624.9M | -0.6% | -$4.8M | $39.6M |
| 2024 Q4 | $1.08B | -0.3% | -$2.4M | $76.5M |
| 2024 Q3 | $654.9M | -0.9% | -$6.5M | -$2.0M |
| 2024 Q2 | -$1.35B | 0.2% | -$5.4M | -$1.5M |
| 2024 Q1 | $535.7M | -0.6% | -$3.6M | $21.9M |